

# Tafenoquine feasibility study in Vietnam

<b>Submission date</b> 27/11/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 07/12/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 05/03/2025	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Malaria is a big health issue in many countries around the world. Among the six types of parasites causing malaria in humans, *Plasmodium vivax* (*P. vivax*) is the second most common after *P. falciparum*, and it's found in the widest range of places. According to the World Health Organization (WHO), there were about 6.4 million cases of *P. vivax* malaria globally in 2019. *P. vivax* infection is marked by the persistence of dormant parasites (called liver-stage hypnozoites), leading to recurring malaria episodes months or even years after the first infection.

This study is looking into the practicality of a new way of treating *P. vivax* malaria. The main goal is to see if this new approach works well in practice, and the secondary goals are to check if it's safe, acceptable, and cost-effective. The new treatment plan includes using a quick test for G6PD and a radical cure treatment with tafenoquine (TQ). The study will roll out this updated plan in health facilities across six districts and also test it in different strategies for finding cases: actively looking for cases, reacting when cases are found, and just waiting for people to come in for treatment. The study will compare how well G6PD testing and TQ work in these different strategies and how much they cost. The evidence collected will be used to inform future decisions. The study will use a mix of methods, including looking at the numbers from case management, talking to people through interviews and group discussions, and comparing costs between the different case-finding approaches.

To make sure the new approach is safe, the study will keep track of patients and deal with any cases of serious side effects. The people involved in the study include those with *P. vivax* malaria, the healthcare workers treating them, and the staff in charge of malaria programs who actively look for cases.

### Who can participate?

Patient with a confirmed *P. vivax* infection, aged 6 months or older.

### What does the study involve?

Patients will be routinely treated according to the national treatment guidelines.

### What are the possible benefits and risks of participating?

None

Where is the study run from?  
PATH (Switzerland)

When is the study starting and how long is it expected to run for?  
June 2023 to December 2025

Who is funding the study?  
Bill and Melinda Gates Foundation (USA)  
Unitaid (Switzerland)

Who is the main contact?  
Dr Thang Tran, thangtran@path.org  
Prof Phuc Bui, phucnimpe@gmail.com

## Contact information

**Type(s)**  
Public, Scientific, Principal investigator

**Contact name**  
Prof Phuc Bui

**Contact details**  
34 Trung Van street, Nam Tu Liem district  
Ha Noi  
Viet Nam  
100000  
+84 983522874  
phucnimpe@gmail.com

**Type(s)**  
Scientific

**Contact name**  
Dr Thang Tran

**Contact details**  
11th floor, 49 Hai Ba Trung Steet, Tran Hung Dao Ward, Hoan Kiem District  
Ha Noi  
Viet Nam  
100000  
+84 913301883  
thangtran@path.org

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

MMV\_TQ\_Vietnam\_2201

## Study information

**Scientific Title**

A mixed-method operational research study on the use of tafenoquine and G6PD testing for radical cure of Plasmodium vivax malaria in passive and active case detection in Vietnam

**Study objectives**

The use of tafenoquine after semi-quantitative G6PD testing for radical cure of Plasmodium vivax malaria is operationally feasible based on the revised algorithm in Vietnam, a country approaching elimination.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

1. approved 25/10/2023, Ethics Review Committee of National Institute of Malariology, Parasitology and Entomology (NIMPE) (34 Trung Van street, Nam Tu Liem district, Ha Noi, 100000, Viet Nam; +84 912216817; thieunq@gmail.com), ref: 407/QD-VSR

2. approved 13/03/2024, Ethics Review Committee of World Health Organization (Avenue Appia 20 1211 Geneva Switzerland, Geneva, 1201, Switzerland; +41 22 791 21 1; evansr@unitaid.who.int), ref: ERC.0003965

**Study design**

Prospective longitudinal operational study with mixed-methods approach including qualitative component quantitative component and costing component

**Primary study design**

Observational

**Study type(s)**

Diagnostic, Treatment

**Health condition(s) or problem(s) studied**

Malaria plasmodium vivax

**Interventions**

Patients will be routinely treated according to the national treatment guidelines in which tafenoquine has been included, we only obtain the informed consent to collect data for assessment of correct indication.

**Intervention Type**

Mixed

**Primary outcome(s)**

Measured using patient records at the end of the study:

1. Proportion of *P. vivax* infected individuals that are correctly treated with TQ based on the revised algorithm as an aggregate and within each of three case finding strategies.
2. Proportion of *P. vivax* and mixed *P. vivax* infected individuals that are correctly treated with PQ based on the revised algorithm as an aggregate and within each of three case finding strategies.

### **Key secondary outcome(s)**

Measured using patient records at the end of the study:

1. Proportion of non-eligible patients that receive Radical Cure (TQ&PQ) treatment
2. Proportion of patients experiencing acute hemolytic anemia (AHA) during the patient follow-up period
3. Health care provider knowledge and skills regarding G6PD testing and radical cure treatment over time as determined by a competency assessment
4. Patients, health care provider and supervisors' perceptions of and experience with the new RC tools, specifically TQ, as reported in interviews and focus group discussions
5. Total monetary cost of including G6PD testing and single dose cure compared across case finding strategies
6. Per patient monetary cost of including G6PD testing and single dose cure compared across case finding strategies.
7. Number of recurrences of *P.vivax* infection reported by study participants during study duration, in total and stratified by treatment type.
8. The number of study participants who present again to the facility or are identified through active case detection methods with a recurrence of *P.vivax* infection during study duration in total and stratified by treatment type.
9. Number of *P. vivax* patients reporting moderate, severe, and serious adverse events after TQ and PQ administration during the study conduct.
10. Frequency and severity of each moderate, severe, and serious adverse event reported after TQ and PQ administration during the study conduct.

### **Completion date**

31/12/2025

## **Eligibility**

### **Key inclusion criteria**

1. Patient with a confirmed *P. vivax* infection.
2. Patients providing informed consent or assent

### **Participant type(s)**

Patient, Health professional, Carer

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

6 months

**Upper age limit**

100 years

**Sex**

All

**Key exclusion criteria**

1. Unwilling to provide informed consent
2. Showing signs of severe infection (patients)

**Date of first enrolment**

15/04/2025

**Date of final enrolment**

30/11/2025

**Locations****Countries of recruitment**

Viet Nam

**Study participating centre**

**National Institute of Malariology, Parasitology and Entomology (NIMPE)**

34 Trung Van street, Nam Tu Liem district

Ha Noi

Viet Nam

100000

**Sponsor information****Organisation**

PATH

**Funder(s)****Funder type**

Charity

**Funder Name**

Bill and Melinda Gates Foundation

**Alternative Name(s)**

Bill & Melinda Gates Foundation, Gates Foundation, Gates Learning Foundation, William H. Gates Foundation, BMGF, B&MGF, GF

### **Funding Body Type**

Government organisation

### **Funding Body Subtype**

Trusts, charities, foundations (both public and private)

### **Location**

United States of America

### **Funder Name**

Unitaid

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date.

### **IPD sharing plan summary**

Data sharing statement to be made available at a later date

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes